Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hESC-derived RPE Transplantation for Retinitis Pigmentosa
NCT03944239Phase 1Active, not recruiting
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASP7317 in retinitis pigmentosa (RP). Primary endpoint: Adverse events and serious adverse events at 1 year. Started May 2021; status: active, not recruiting.
02
Drugs
ASP7317
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT03944239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944239.